Abstract
Purpose
To evaluate the clinicopathological features, the role of neo-adjuvant and adjuvant treatment and recurrence patterns in patients with low-grade endometrial stromal sarcomas (LGESS).
Materials and Methods
Medical records of LGESS patients treated at gynec oncologic referral center between January 1, 2014, and October 31, 2021, were retrospectively reviewed.
Statistical Analysis
Recurrence-free survival (RFS) was calculated using the Kaplan–Meier method. Differences between survival curves were assessed using the log-rank test.
Results
A total of 21 consecutive patients with LGESS were identified. The mean age of presentation was 44.3 years (standard deviation of 10.26). The most common presenting complaint was abnormal uterine bleeding in 10 (47.6%) of 21 patients. Fourteen (67%) of 21 patients belonged to FIGO stage I and II. The mainstay of the treatment was total hysterectomy with bilateral salpingo-oophorectomy in all the 21 patients. Three (14.2%) patients with clinically and radiologically inoperable disease, started on neo-adjuvant hormone treatment for 8 weeks, underwent cytoreductive surgery with no residual disease. Recurrence-free survival (RFS) in the observation group of LGESS following surgery was 28 months while the RFS was 40 months if any adjuvant treatment was offered after surgery.
Conclusion
The cornerstone of management remains total hysterectomy with bilateral salpingo-oophorectomy. The use of neo-adjuvant hormone therapy in LGESS is strongly advocated in cases where it is deemed clinically and radiologically inoperable.
Similar content being viewed by others
References
Conklin CM, Longacre TA. Endometrial stromal tumors: the new WHO classification. Adv Anat Pathol. 2014;21(6):383–93. https://doi.org/10.1097/PAP.0000000000000046.
Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO classification of female genital tumors. Geburtshilfe Frauenheilkd. 2021;81(10):1145–53. https://doi.org/10.1055/a-1545-4279.
Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355–64. https://doi.org/10.1111/j.1365-2559.2009.03231.x.
Seagle BL, Shilpi A, Buchanan S, Goodman C, Shahabi S. Low-grade and high-grade endometrial stromal sarcoma: a national cancer database study. Gynecol Oncol. 2017;146(2):254–62. https://doi.org/10.1016/j.ygyno.2017.05.036.
Puliyath G, Nair MK. Endometrial stromal sarcoma: a review of the literature. Indian J Med Paediatr Oncol. 2012;33(1):1–6. https://doi.org/10.4103/0971-5851.96960.
Ashraf-Ganjoei T, Behtash N, Shariat M, Mosavi A. Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol. 2006;4:50. https://doi.org/10.1186/1477-7819-4-50.
Jin Y, Pan L, Wang X, et al. Clinical characteristics of endometrial stromal sarcoma from an academic medical hospital in China. Int J Gynecol Cancer. 2010;20(9):1535–9.
Koss LG, Spiro RH, Brunschwig A. Endometrial stromal sarcoma. Surg Gynecol Obstet. 1965;121:531–7.
Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr. Treatment of endometrial stromal tumors. Gynecol Oncol. 1990;36(1):60–5. https://doi.org/10.1016/0090-8258(90)90109-x.
Scribner DR Jr, Walker JL. Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace. Gynecol Oncol. 1998;71(3):458–60. https://doi.org/10.1006/gyno.1998.5174.
Thanopoulou E, Judson I. Hormonal therapy in gynecological sarcomas. Expert Rev Anticancer Ther. 2012;12(7):885–94. https://doi.org/10.1586/era.12.74.
Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM. Progesterone receptor expression is an independent prognosticator in FIGO stage I uterine leiomyosarcoma. Am J Clin Pathol. 2016;145(4):449–58. https://doi.org/10.1093/ajcp/aqw030.
Lange SS, Novetsky AP, Powell MA. Recent advances in the treatment of sarcomas in gynecology. Discov Med. 2014;18(98):133–40.
National Comprehensive Cancer Network. Uterine neoplasms. Version 2, 2021 https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf
Huang X, Peng P. Hormone therapy reduces recurrence in stage II-IV uterine Low-grade endometrial stromal sarcomas: a retrospective cohort study. Front Oncol. 2022;12:922757. https://doi.org/10.3389/fonc.2022.922757.
Smith ES, Jansen C, Miller KM, et al. Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma. Int J Gynecol Cancer. 2022;32(7):882–90. https://doi.org/10.1136/ijgc-2022-003383.
Author information
Authors and Affiliations
Contributions
RAS contributed to data collection, manuscript writing and literature reviewing. BMP, PD contributed to data collection, manuscript writing and proof reading. SMP contributed to data collection.
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors the corresponding author declares there is no conflict of interest.
Ethical Approval
The need for ethical approval was waived due to retrospective nature of analysis. All data were anonymized before analysis. The study was performed in accordance with ethical standards laid down in 1964 Declaration of Helsinki and its latter amendments. Institutional Review Committee (IRC) has approved the article for journal submission. The (IRC) number for this submission is IRC/2023/P-46.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Abdul Shukur, R., Patel, B.M., Dave, P. et al. A Retrospective Observational Study on Clinicopathological Features, Optimal Management and Recurrence Patterns in Low-Grade Endometrial Stromal Sarcoma. Indian J Gynecol Oncolog 21, 77 (2023). https://doi.org/10.1007/s40944-023-00759-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40944-023-00759-9